Featured Stories
块连VPN框架
Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan.
read more ...
块连VPN框架
Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration has been announced.
read more ...
Corporate Governance Report has now been updated.
read more ...
Disposal of Treasury Shares as Restricted Share-Based Remuneration has been announced.
read more ...
ASCO 2023 Highlight materials are now available.
read more ...
Convocation Notice of the 15th Ordinary General Meeting of Shareholders is now available.
read more ...
FY2023 Q4 financial results are now available.
read more ...
Featured News
- Index
- E-mail Alert
- RSS
2023.07.27 |
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 |  |
| 2023.07.22 |
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan | |
2023.07.21 |
Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients | |
| 2023.07.10 |
Daiichi Sankyo Announces Participation in AMR Action Fund | |
| 2023.07.07 |
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer | |
| 2023.07.02 |
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer | |
| 2023.06.29 |
Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT | |
| 2023.06.26 |
Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Corona Virus Vaccine | |
在线伋理服务器免费网页版
- Index
- RSS
2023.06.15 |
Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 13th Annual Clinical Pharmacology Research Award |
| 2023.06.12 |
R&D Activities for COVID-19 Vaccines and Therapeutics |
| 2023.04.22 |
Daiichi Sankyo Announces Collaborative Research with DNDi on Drugs for Neglected Tropical Diseases |
| 2023.04.13 |
Our Company’s Efforts to Limit the Spread of the Virus that Causes COVID-19 |
块连VPN框架
块连VPN框架
Who We Are
Our People
Partnerships
国外伋理服务器ip免费
Daiichi Sankyo Library
块连VPN框架
Our Approach
Pipeline
Open Innovation
TaNeDS Global
块连VPN框架
Media Relations
Investor Relations
块连VPN框架
CSR TOP
Responsible Corporate Activities
CSR Activities in Six Priority Areas
在线伋理服务器免费网页版
香港伋理服务器ip免费
Reports